MORTON
GROVE, Ill., Nov. 26,
2024 /PRNewswire/ -- Lifeway Foods, Inc. (NASDAQ:
LWAY) (the "Company" or "Lifeway"), the leading U.S. supplier of
kefir and fermented probiotic products to support the microbiome,
today provided additional information regarding the reasons that
its Board of Directors rejected the revised unsolicited proposal
made on November 15, 2024 by Danone
North America PBC ("Danone") to acquire all the shares of Lifeway
that it does not already own for $27.00 per share.
The Board determined that Danone's $27.00 per share proposal substantially
undervalues the Company. The Board is not, however, opposed to the
sale of the Company at any price.
The Board has carefully evaluated the Company's standalone
plan and believes it has strong potential to provide superior
value to all shareholders as compared to Danone's revised proposal.
The Board takes its fiduciary duties seriously and is committed to
acting in the best interests of all of the Company's shareholders
and other stakeholders.
Lifeway Foods is the number one kefir brand and is
experiencing double-digit growth, which is eclipsing much of the
rest of the dairy and food industry. As Lifeway's strong
historical financial results indicate, the Company has sustained
momentum with runway for significant long-term growth and
margin expansion. This growth is being driven by an increasing
recognition among consumers of the importance of the gut microbiome
to overall health and the benefits of the naturally available
high-quality protein and probiotics contained in kefir. A growing
body of scientific research supports these benefits and speaks to
the unique value proposition of Lifeway.
In reaching its determination regarding Danone's revised
proposal, the Board also took into account the
following:
- Lifeway has achieved 20 consecutive fiscal quarters of
year-over-year topline growth.
- Over the past five years, Lifeway achieved a total
shareholder return of 788% (as measured through September 23, 2024, the last full trading day
before Danone's initial unsolicited proposal was publicly
disclosed), far outperforming other high growth food and beverage
peers as well as the S&P 500.
- From 2019 to 2023, the Company's annual revenue has grown from
$94 million to $160 million, a 71% increase and a 14% cumulative
annual growth rate ("CAGR").
- Over that same five-year period, gross profit increased 92%,
representing an 18% CAGR, with continued Operating Income and
Adjusted EBITDA1 margin expansion over the same period
achieving $17 million in Operating
Income and $22 million in Adjusted
EBITDA in 2023.
- The Board and management believe that Lifeway has reached
an inflection point, with strong momentum in core kefir products,
new product adjacencies and ongoing operational efficiency
programs, which have rapidly improved profitability and which the
Company expects to continue to rapidly improve profitability.
- Lifeway forecasts annual Adjusted EBITDA to grow from
$22 million in 2023 to between
$45 million and $50 million in 2027.
- Based on the expected 2027 EBITDA range, the Danone
proposal of $27 per share implies a
very low multiple of ~7.5x – 8.5x EBITDA, even prior to accounting
for substantial synergies and additional operational efficiencies
that Danone (or another strategic acquirer) could realize.
The Company does not provide guidance for GAAP Operating Income,
nor a reconciliation of any forward-looking non-GAAP financial
measures to the most directly comparable GAAP financial measures on
a forward-looking basis, because it is unable to predict certain
items contained in the GAAP measures without unreasonable efforts.
These forward-looking non-GAAP financial measures do not include
certain items, which may be significant, including, without
limitation, non-recurring or non-operational expenses such as
stock-based compensation, gain/loss on sale of equipment, deferred
revenue and gain/loss on investments prior to payment of bonuses to
employees.
Lifeway's Board and management are committed to ensuring that
all shareholders are able to realize the full potential value of
their investment.
Evercore is serving as a financial advisor to Lifeway, and
Sidley Austin LLP is serving as legal counsel to Lifeway.
About Lifeway Foods, Inc.
Lifeway Foods, Inc.,
which has been recognized as one of Forbes' Best Small Companies,
is America's leading supplier of the probiotic, fermented beverage
known as kefir. In addition to its line of drinkable kefir, the
company also produces a variety of cheeses and a ProBugs line for
kids. Lifeway's tart and tangy fermented dairy products are now
sold across the United
States, Mexico, Ireland, South Africa, United
Arab Emirates and France. Learn how Lifeway is good for
more than just you at lifewayfoods.com.
Forward-Looking Statements
This release contains
"forward-looking statements" within the meaning of Section 27A of
the Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended. Forward-looking
statements include all statements that are not historical
statements of fact and those regarding Lifeway's
intent, belief, plans or expectations for Lifeway's
business, operations, financial performance or condition,
including, without limitation, statements regarding expected growth
in profitability and forecasted Adjusted EBITDA. These statements
use words such as "continue," "believe," "expect," "anticipate,"
"plan," "project," "estimate," "outlook," "potential," "forecast"
and similar expressions or future or conditional verbs such as
"will," "should," "would," "may" and "could." You are cautioned not
to rely on these forward-looking statements. These forward-looking
statements are made as of the date of this press release, are based
on current expectations of future events and thus are inherently
subject to a number of risks and uncertainties, many of which
involve factors or circumstances beyond Lifeway's
control. If underlying assumptions prove inaccurate or known
or unknown risks or uncertainties materialize, actual results could
vary materially from Lifeway's expectations and
projections. These risks, uncertainties and other factors include:
price competition; the decisions of customers or consumers; the
actions of competitors; changes in the pricing of commodities; the
effects of government regulation; possible delays in the
introduction of new products; customer acceptance of products and
services; and other factors discussed in Part I, Item 1A "Risk
Factors" of Lifeway's Annual Report on Form 10-K for
the fiscal year ended December 31,
2023 and Part II, Item 1A "Risk Factors" of Lifeway's
Quarterly Report on Form 10-Q for the fiscal quarter ended
September 30, 2024. Lifeway
expressly disclaims any obligation to update any
forward-looking statements (including, without limitation, to
reflect changed assumptions, the occurrence of anticipated or
unanticipated events or new information), except as required by
law.
Non-GAAP Financial Measures
This press release refers
to Adjusted EBITDA, which is a financial measure that has not been
prepared in accordance with U.S. Generally Accepted Accounting
Principles ("GAAP") and may exclude items that are significant to
understanding and assessing financial results. This non-GAAP
measure is provided to enhance investors' overall understanding of
the Company's financial performance. Non-GAAP financial measures
should be considered as supplements to GAAP measures reported,
should not be considered replacements for, or superior to, GAAP
measures reported and may not be comparable to similarly named
measures used by other companies. The Company's calculation of
non-GAAP financial measures may differ from methods used by other
companies. A reconciliation of non-GAAP measures to the most
directly comparable GAAP measures is included in the accompanying
table.
Reconciliation of Non-GAAP Financial Measures to Reported
Financial Measures
Adjusted EBITDA*
(In
millions)
|
2019
|
2020
|
2021
|
2022
|
2023
|
Operating Income
(GAAP)
|
($1.9)
|
$4.9
|
$5.9
|
$2.3
|
$17.0
|
Depreciation
|
3.1
|
3.1
|
2.8
|
2.4
|
2.6
|
Amortization
|
0.2
|
0.2
|
0.1
|
0.5
|
0.5
|
Stock-Based
Compensation
|
0.8
|
0.4
|
1.1
|
1.1
|
1.5
|
Adjusted EBITDA
(non-GAAP)**
|
$2.2
|
$8.6
|
$9.9
|
$6.4
|
$21.7
|
* Adjusted EBITDA is defined as Operating Income, as
reported, plus Depreciation and Amortization, plus Stock-Based
Compensation. Management believes that presentation of Adjusted
EBITDA provides helpful supplemental information to investors
regarding the Company's profitability. Adjusted EBITDA is used in
the Company's executive compensation program as a means of
incentivizing the driving of short-term and long-term growth.
** Totals may not sum due to rounding.
Contacts:
Derek
Miller
Vice President of Communications, Lifeway Foods
Email: derekm@lifeway.net
OR
Longacre Square Partners
Joe Germani / Miller Winston
Email: LWAY@longacresquare.com
1 Adjusted EBITDA is a non-GAAP financial measure.
Adjusted EBITDA is defined as Operating Income, as reported, plus
Depreciation and Amortization, plus Stock-Based Compensation. See
the accompanying tables for reconciliations of Adjusted EBITDA
to Operating Income.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/lifeway-provides-additional-information-regarding-reasons-for-rejecting-danones-revised-proposal-302316488.html
SOURCE Lifeway Foods, Inc.